SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 166 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 2.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,024,183 | -19.4% | 70,536 | +16.1% | 0.04% | -20.8% |
| Q2 2023 | $1,271,351 | +17.1% | 60,743 | +18.1% | 0.05% | +6.7% |
| Q1 2023 | $1,086,096 | +53.2% | 51,425 | +26.0% | 0.04% | +60.7% |
| Q1 2022 | $709,000 | +39.0% | 40,804 | +75.1% | 0.03% | +21.7% |
| Q4 2021 | $510,000 | +78.9% | 23,298 | +40.3% | 0.02% | +27.8% |
| Q2 2021 | $285,000 | -45.5% | 16,609 | -28.9% | 0.02% | -30.8% |
| Q1 2021 | $523,000 | +32.1% | 23,368 | +31.2% | 0.03% | +52.9% |
| Q4 2020 | $396,000 | – | 17,816 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |